Literature DB >> 32016032

The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases.

Jaleh Fallah1, Manmeet S Ahluwalia1,2.   

Abstract

Entities:  

Year:  2019        PMID: 32016032      PMCID: PMC6976477          DOI: 10.21037/atm.2019.10.31

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  18 in total

1.  The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.

Authors:  Maxine Sun; Guillermo De Velasco; Priscilla K Brastianos; Ayal A Aizer; Allison Martin; Raphael Moreira; Paul L Nguyen; Quoc-Dien Trinh; Toni K Choueiri
Journal:  Eur Urol Focus       Date:  2018-01-05

2.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Authors:  Harriet M Kluger; Veronica Chiang; Amit Mahajan; Christopher R Zito; Mario Sznol; Thuy Tran; Sarah A Weiss; Justine V Cohen; James Yu; Upendra Hegde; Elizabeth Perrotti; Gail Anderson; Amanda Ralabate; Yuval Kluger; Wei Wei; Sarah B Goldberg; Lucia B Jilaveanu
Journal:  J Clin Oncol       Date:  2018-11-08       Impact factor: 44.544

3.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

4.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Authors:  Hussein A Tawbi; Peter A Forsyth; Alain Algazi; Omid Hamid; F Stephen Hodi; Stergios J Moschos; Nikhil I Khushalani; Karl Lewis; Christopher D Lao; Michael A Postow; Michael B Atkins; Marc S Ernstoff; David A Reardon; Igor Puzanov; Ragini R Kudchadkar; Reena P Thomas; Ahmad Tarhini; Anna C Pavlick; Joel Jiang; Alexandre Avila; Sheena Demelo; Kim Margolin
Journal:  N Engl J Med       Date:  2018-08-23       Impact factor: 91.245

5.  Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Authors:  Ronan Flippot; Cécile Dalban; Brigitte Laguerre; Delphine Borchiellini; Gwénaelle Gravis; Sylvie Négrier; Christine Chevreau; Florence Joly; Lionnel Geoffrois; Sylvain Ladoire; Hakim Mahammedi; Frédéric Rolland; Marine Gross-Goupil; Elise Deluche; Frank Priou; Mathieu Laramas; Philippe Barthélémy; Bérengère Narciso; Nadine Houedé; Stéphane Culine; Stéphane Oudard; Marina Chenot; Florence Tantot; Sylvie Chabaud; Bernard Escudier; Laurence Albiges
Journal:  J Clin Oncol       Date:  2019-06-13       Impact factor: 44.544

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

8.  Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

Authors:  Linda Chen; Jacqueline Douglass; Lawrence Kleinberg; Xiaobu Ye; Ariel E Marciscano; Patrick M Forde; Julie Brahmer; Evan Lipson; William Sharfman; Hans Hammers; Jarushka Naidoo; Chetan Bettegowda; Michael Lim; Kristin J Redmond
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-05       Impact factor: 7.038

9.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Authors:  Georgina V Long; Victoria Atkinson; Serigne Lo; Shahneen Sandhu; Alexander D Guminski; Michael P Brown; James S Wilmott; Jarem Edwards; Maria Gonzalez; Richard A Scolyer; Alexander M Menzies; Grant A McArthur
Journal:  Lancet Oncol       Date:  2018-03-27       Impact factor: 41.316

10.  Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.

Authors:  Aditya Juloori; Jacob A Miller; Shireen Parsai; Rupesh Kotecha; Manmeet S Ahluwalia; Alireza M Mohammadi; Erin S Murphy; John H Suh; Gene H Barnett; Jennifer S Yu; Michael A Vogelbaum; Brian Rini; Jorge Garcia; Glen H Stevens; Lilyana Angelov; Samuel T Chao
Journal:  J Neurosurg       Date:  2019-01-18       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.